Premium
Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells
Author(s) -
Kivivuori SannaMaria,
Siitonen Sanna,
Porkka Kimmo,
Vettenranta Kim,
Alitalo Riitta,
SaarinenPihkala Ulla
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20857
Subject(s) - angiogenesis , medicine , cancer research , receptor tyrosine kinase , haematopoiesis , bone marrow , vascular endothelial growth factor , leukemia , kinase insert domain receptor , tyrosine kinase , myeloid , pathology , receptor , vascular endothelial growth factor a , immunology , biology , stem cell , microbiology and biotechnology , vegf receptors
Abstract Background Recent data indicate a role for angiogenesis in hematologic malignancies. In addition to promoting new vessel growth in the bone marrow microenvironment, angiogenic factors are regulators of both hematopoietic and leukemic cells. Activation of vascular endothelial growth factor receptor 3 (VEGFR‐3) and Tie1 tyrosine kinase receptor are known to promote leukemia cell survival. The details of this complex angiogenesis‐related interaction are still uncertain. Procedure We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods. Results Vascular endothelial growth factor receptor 3 expression was found in 15% of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs. Tie1 protein expression was found in 11% of the samples, all of which were from adult AML patients. Conclusions Our findings suggest that there are angiogenesis‐related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias. Pediatr Blood Cancer © 2006 Wiley‐Liss, Inc.